BOLD | Boundless Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5400 - 1.7700
52 Week Range	1.0600 - 12.26
Beta	2.14
Implied Volatility	6.52%
IV Rank	24.51%
Day's Volume	123,896
Average Volume	72,195
Shares Outstanding	22,300,043
Market Cap	39,248,076
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-07-20

Valuation
Profitability
Growth
Health
P/E Ratio	-0.46
Forward P/E Ratio	N/A
EPS	-3.85
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	72
Country

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

*Chart delayed

Analyzing fundamentals for BOLD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see BOLD Fundamentals page.

Watching at BOLD technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on BOLD Technicals page.